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A strain of rabbits with an inherited complement defect (1) has been shown 
to be deficient in the sixth component of complement (C6) hemolytic activity 
(2, 3). No protein immunochemically related to C6 is present in plasma from 
these animals and they are able to produce antibody to rabbit C6 (2, 4). 
In this communication  we report investigations of a coagulation abnormality 
we have found in blood from these animals. Our results provide direct evidence 
for an involvement of C6 in normal blood coagulation. 
Materials and Methods 
Venous Blood.--Venous blood from normal New Zealand white rabbits and rabbits deficient 
in C6 (1) (purchased from Rancho de Conejo, Vista, Calif.) was withdrawn from the hind leg 
vein with a 19 gauge small vein infusion set (McGaw Laboratories Inc., Glendale, Calif.) and 
disposable polypropylene syringes (Sherwood Medical Industries Inc., Deland, Fla.).  Blood 
for measurement of whole blood clotting time and prothrombin consumption was immediately 
placed in the appropriate incubation tubes  (see below). Blood drawn from ear arteries had 
consistently shorter clotting times than leg vein blood, suggesting contamination  with tissue 
juices. No more than 12 ml was withdrawn at on  e time as the prolonged venesection required 
for obtaining larger quantities of blood was associated with a shortening of the clotting time. 
Blood to provide plasma for coagulation studies was mixed with one-fiftieth volume of 0.5 M 
sodium citrate buffer (pH 5.0) in 12 X 75-ram polypropylene tubes (Falcon Plastics, Oxnard, 
Calif.). Platelet-poor plasma was separated by centrifugation at 3500 g for 15 rain in an Inter- 
national refrigerated centrifuge, PR-2  (International Equipment Company, Boston, Mass.). 
Platelet-rlch plasma was separated from whole blood by centrifugation at a force of 850 g for 
10 min. 
Clotting Time.--Clotting time of 1 ml aliquots of whole blood was determined in 10 )< 75- 
mm disposable glass culture tubes  (Corning Glass Works, Coming, N.Y.)  and 12 )< 75-mm 
polypropylene tubes  (Falcon Plastics) at 25°C (5). A serial, three-tube technique was used 
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with observation for clotting every minute in glass tubes and every 10 min in polypropylene 
tubes. Tubes were tapped against the side of the water bath to determine when a solid clot 
filled the entire volume. Formation of this solid clot was taken as the end point. 
The effect of highly purified C6 on whole blood clotting time in polypropylene tubes was 
determined by adding C6 or buffer as a control to each of three tubes before adding the blood. 
The tubes were then tapped gently to achieve mixing and observed for clotting. 
Recalcified  clotting time of 0.2 ml plasma aliquots was determined in duplicate 10  X  70- 
mm disposable glass tubes. Plasma was kept at  4°C until addition of 0.2 ml of 0.025 M CaC12, 
also kept at 4°C. The tubes were then transferred immediately to a 25°C water bath and  ob- 
served for clotting every 60 sec.  ~ 
Prothrombin (Factor II)  Consumptlon.--Protrombin  (factor II)  consumption was  deter- 
mined in triplicate 1 ml aliquots of whole blood and results are expressed as the mean. The 
blood was incubated in three  12  X  75-mm  polypropylene tubes for 60  min at  37°C,  then 
placed in an ice water bath and 0.04 ml of 0.5 ~  sodium citrate added to each tube. The clots 
were broken up with birch applicator sticks and the tubes incubated at 37°C for 30 min to 
inactivate thrombin. After centrifugation at 3500 g, the supernatant serum was assayed for 
prothrombin (see below).  1 ml of blood, obtained at the same time as the previous samples, 
was also added to 0.04 ml of 0.5 M sodium citrate in a  12  X  75 mm polypropylene tube and 
carried through the  same incubations. The prothrombin activity in  the plasma from this 
blood was assigned the value of 100%  and appropriate dilutions were used to construct a 
calibration  curve.  Prothrombin consumption was  calculated  by  subtracting  the per  cent 
prothrombin detectable on assay from 100. 
The effect of highly purified C6 on prothrombin consumption in whole blood was measured 
by adding either C6 or buffer to duplicate tubes before the addition of blood.  Mixing was 
achieved by gentle tapping. This agitation sometimes accelerated prothrombin consumption 
in tubes containing buffer only.  Incubation times were therefore shortened to approximately 
40  min so that less than 5% prothrombin was consumed in tubes containing buffer only. 
Other Coagulation Assays.--The partial thromboplastin time without kaolin, prothrombin 
time, and assays for stable factor  (factor VII), prothrombin (factor II),  and Stuart  factor 
(factor X) were performed as described in a standard text  (6)  using artificial  substrates for 
factor I[ and factor X, as indicated in the text and using canine plasma congenitally deficient 
in factor VII for assay of that factor. Labile factor (factor V) was assayed in the same manner, 
except that aged, oxalated human plasma (7) was used as a substrate. The assays of Hageman 
factor (factor XII), plasma thromboplastin antecedent (PTA)  (factor XI), Christmas factor 
(factor IX), and antihemophilic factor (factor VIII)  were performed as described (8)  using 
as substrates human plasma congenitally deficient in  the factor being assayed. Thrombin 
time (9), Russell's viper venom time of unabsorbed platelet-poor plasma (10), thromboplastin 
generation test (11, 12), kaolin-activated Russell's viper venom time of platelet-rich plasma 
(13),  clot retraction of blood clotted with tissue thromboplastin (14), platelet count  (15), 
and platelet aggregation (16) also were performed by techniques described by others. Bleeding 
time was measured after incision of a  toe pad with a  No.  11  scalpel blade  (Bard-Parker, 
Rutherford, N.J.). Blood was removed from the wound every 20 sec with filter paper, taking 
care not to touch the wound itself. 1 
Isolated C6.--The method of isolation of C6 has been described in detail elsewhere (17). 
1 ml  aliquots of isolated C6 were dialyzed against  1000 ml  of tris(hydroxymethyl)amino- 
methane (Tris)  saline buffer (0.05 ~  Tris, 0.1 ~t sodium chloride, pH 7.0) or barbital-buffered 
saline (0.05 ~t sodium barbital, 0.1 ~  sodium chloride, pH 7.5) for 24 hr before use and the 
dialysis buffer was used as control buffer for these studies. 
Molecular Sieve Chromatography.--850 #g  of highly purified C6  or 4000/zg  of partially 
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purified  C6  were applied  to  a  5 )< 100  cm  Sephadex  G-200  (Pharmacia  Fine  Chemicals, 
Piscataway,  N.J.)  column equilibrated  with  barbital-buffered  saline  and  the  effluent was 
collected in 2-ml fractions at  a  flow rate  of 30  ml/hr. 
C6 Hemolytic Activity.--C6 hemolytic activity was measured in a 0.5 ml reaction mixture 
containing 100 #1 sample, C6-deficient rabbit  serum in a final dilution of 1:20 and 5 )<  10 7 
sensitized sheep  erythrocytes, or with sensitized cells and purified complement components 
(17). 0.15 ~ barbital buffer, pH 7.5, was used which contained 0.00015 M CaC12 and 0.000059 
~t MgCI~. The mixture was incubated at 37°C for 30 min and then brought to 2 ml with cold 
(4°C)  saline  and  centrifuged.  The  degree of hemolysis was  determined  by measuring free 
hemoglobin in the supernatant  at  541  ~  on  a  Coleman Jr.  II spectrophotometer,  Model 
635  (Coleman  Instruments,  Maywood,  Ill.). 
Consumption of Complement Component Activities.--Consumption of  complement  com- 
ponent  activities during blood coagulation was determined  on human  venous blood drawn 
from the antecubital vein with a 19 gauge small vein infusion set and disposable polypropyiene 
syringes.  The blood was treated as for the determination of prothrombin consumption with 
the exception that 10  )< 75-ram glass tubes were used for incubation. Except where indicated, 
the blood was allowed to clot for 2 hr at 37°C. The complement activities in serum were then 
compared with the activities in citrated plasma which had been allowed to incubate for 2 hr 
at 37°C before separation  from the formed blood elements. 
Assays of Complement Components.--Assays of complement components C2, C8,  C9  (18), 
and  C7 ~ have  been  described  elsewhere. 
Protein.--Protein was measured  by the method  of Lowry et  al.  (19) using purified  C3 
as a standard. 
Polyacrylamide-Gd Electrophoresis.--Polyacrylamide-gel electrophoresis  was  carried  out 
by the method of Davis (20) employing a polyacrylamide concentration of 6% in the separa- 
tion gel. Buffalo black was used as the stain. 
RESULTS 
Blood  Coagulation  Studies  in  C6-Deficient  and  Normal  Rabbits.--Clotting 
time  of whole blood  in  glass  and  plastic  tubes  was  consistently  prolonged  in 
C6-deficient rabbits  and prothrombin  consumption markedly decreased  (Table 
I). When normal and C6-deficient rabbit blood were mixed in equal quantities 
before  incubation,  partial  correction  of  the  prothrombin  consumption  abnor- 
mality was  achieved.  Clotting time of blood from a  Cr-deficient rabbit,  blood 
from a  normal rabbit,  and a  mixture of equal parts  of Cr-deficient and normal 
blood  were  respectively  >230,  80,  and  110  rain.  Prothrombin  consumption 
was 0, 60, and 41%. 
No  other  coagulation  abnormalities  were  demonstrated.  In  a  typical  C6- 
deficient rabbit  the prothrombin  time was  12.4  sec with  a  control of  12.2  sec. 
The partial  thromboplastin  time was  58  sec with  a  control of 62  sec. The re- 
calcified clotting time was 4  rain with a  control of 3.5 min. The Russell's viper 
venom  time  on  platelet-poor  plasma  was  12.6  sec with  a  control  of  12.2  sec. 
Thrombin  time was 26 sec with a  control of 30 sec. Specific coagulation factor 
activity assays were all normal. The factor II (prothrombin)  activity was 100 % 
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the  factor V  (proaccelerin),  100%;  the  factor VII  (stable  factor),  70%;  the 
factor VIII (antihemophilic factor),  80%;  the  factor IX  (Christmas  factor), 
> 100%; the factor X  (Stuart factor),  100%; the factor XI (PTA),  > 100%; 
and factor XII (Hageman factor),  > 100 % of a normal rabbit. 
Platelet factor III activity as measured in the thromboplastin generation test 
and kaolin-activated Russell's viper venom time was  also normal. In the 6 min 
thromboplastin generation test using autologous platelets, the substrate clotting 
time was 20 sec with a  control of 19 sec.  The kaolin-activated Russell's viper 
venom time was 18 sec with a control of 20 sec in  platelet-rich plasma. Other 
normal platelet parameters  include a platelet count of 485,000 with a control of 
525,000  and normal platelet aggregation with adenosine 5'-diphosphate (Sigma 
Chemical Co.,  St. Louis, Mo.)  and collagen (Sigma).  Clot retraction of blood 
clotted with  tissue  thromboplastin  was normal with  78%  of serum expressed 
TABLE I 
Abnormal Clotting Time and Prothrombin Consumption in C6-Deficient rabgits* 
Clotting time 
C6 deficient  Normal 
Glass  Plastic  Glass  Plastic 
Prothrombin consumption 
C6 Deficient  Normal 
miu  % 
39  >400  23  90  0  78.5 
34  170  20  90  4  75.5 
38  >340  24  90  0  76 
41  160  24  70  0  75 
40  140  31  70  0  68 
10  60 
* Each value represents a determination on an individual animal. 
from the clot as  compared to 80% in  the control. Bleeding time was  180 sec 
with a  control of 160 sec. 
The ~rect of Highly  Purified C6 on  Blood Coagulation  in C6-Deficient Rab- 
bits.--Preparations  of highly purified human or rabbit  C6 were  analyzed for 
homogeneity by polyacrylamide-gel electrophoresis. No contaminants could be 
detected in the 50 to 100-/~g samples applied to the gels (Fig. 1). There was no 
detectable clotting factor activity in a typical preparation containing 450/~g of 
protein/ml which was assayed undiluted (Table II). 
Addition  of highly purified  C6  to  blood  of  C6-deficient  rabbits  markedly 
shortened  the  clotting  time  and  accelerated  the  prothrombin  consumption. 
Addition of 30 #g of C6 in 0.25 nil of buffer shortened the plastic tube clotting 
time to  100 min from 200  min  (when buffer  alone was added).  Prothrombin 
consumption was increased to 80%  when 45/~g  of C6 in 0.1 ml of buffer was 
added. No prothrombin was consumed when only buffer was added. The effect ZI3IMERMAN, ARROYAVE~ Mi]TLLER-EBERHARD  1595 
of C6  on prothrombin  consumption is a function fo the  amount  of C6  added 
(Fig. 2). The clot-promoting activity was detectable even in amounts less than 
the quantities present in normal blood (25-50 #g/ml of blood).3 
An effect of highly purified C6 could also be demonstrated on normal rabbit 
blood if incubation times were shortened. When 1 ml of normal blood was incu- 
bated with 0.05 ml of buffer for 15 min, 30% of prothrombin was consumed as 
opposed to 88 % when C6 (450 #g/ml of buffer) was added. 
FIG. 1. Polyacrylamide-gel  electrophoresis of C6 preparations. The first preparation  (left) 
was obtained from rabbit serum, the second two from human serum. 
The C6 hemolytic and clot-promoting activities remained together during the 
purification  process.  Filtration  of  a  partially purified  preparation  through  a 
Sephadex G-200 column resulted in the separation of most of the protein from 
the  hemolytic  and  clot-promoting  activities,  but  not  in  separation  of  these 
activities from each other (Fig. 3). When a highly purified preparation with only 
one protein band on polyacrylamide-gel electrophoresis was similarly subjected 
to molecular sieve chromatography, an excellent correlation was obselared be- 
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tween  the  distribution  of protein,  C6  hemolytic activity,  and  clot-promoting 
activity (Fig. 4). 
Consumption  of  Complement  Component  Hemolytic  Activities  during  Blood 
Coagulation.--Both  C6  and  C7  hemolytic  activities  were partially  consumed 
during  the  process  of blood  coagulation.  C6  activity  diminished  13.3-14.5 % 
TABLE II 
Lack of Classical Clotting Factor Activity in a Highly Purified Preparation of C6" 
Factor  Units of activity:~ 
II  <0.01 
V  <0.01 
VII  <0.01 
VIII  <0.01 
IX  <0.01 
X  <0.01 
Xl  <0.01 
XlI  <0.01 
* The protein concentration was 450 #g/ml. 
:~ 1 unit of activity is defined as the activity in 1 ml normal rabbit plasma. 
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FIG. 2. The relationship of prothrombin consumption in C6-deficient plasma to the quantity 
of isolated C6 added. 
and C7 decreased 7-10 % during 10 separate experiments. A similarity between 
the time course of consumption of C6 hemolytic activity and prothrombin was 
observed (Fig. 5). No consumption of C2, C8, or C9 was demonstrated. 
DISCUSSION 
The  demonstration  of prolonged  clotting times and retarded prothrombin 
consumption in rabbits deficient in the sixth component  of complement  and the ZIMMERMAN,  ARROYAVE,  M/ZLLER-EBERHARD  1597 
correction of these abnormalities with highly purified C6 suggests that this pro- 
tein is a  normal participant in the blood coagulation mechanism. The partial 
consumption  of C6  hemolytic activity during  blood coagulation  with  a  time 
course parallel to that of prothrombin consumption provides further evidence 
for this concept. 
It is possible, but improbable, that, in addition to the C6 deficiency, another 
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genetic abnormality is present in these animals accounting for the coagulation dis- 
order. Such an explanation implies that the second gene product is indistinguish- 
able from C6 by present physicochemical techniques. It seems unlikely that the 
clot-promoting effect of the C6 preparations is due to the presence of a contami- 
nating protein. The  C6 hemolytic and clot-promoting activities remained as- 
sociated during the purification of the protein, and no classical clotting factor 
activity could  be detected  in  the  highly purified preparations.  The clot-pro- 1598  BLOOD  COAGULATION  ABNORMALITY  IN  C6  DEFICIENCY 
moting activity of highly purified C6 strongly implies that the absence of C6 
protein in the deficient rabbits is responsible for their coagulation abnormality. 
A possible role of complement in blood coagulation has been previously sug- 
gested by the demonstration of shortening of whole rabbit blood clotting time 
with antigen-antibody complexes (21).  The participation of complement (C3 
and C4) in the lysis of dilute blood clots has been demonstrated previously (22). 
Our findings show that C6 may be involved in blood coagulation even without 
the participation of  antigen-antibody reactions,  and  thus  indicate  a  role in 
normal blood clotting. The partial consumption of C7,  as well as C6, during 
blood coagulation suggests that both components may be involved. The exact 
mechanism of complement participation in  coagulation and possible involve- 
ments of other complement components is under study. 
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FIG.  5.  Time course of consumption of C6 hemolytic  activity  and prothrombin during the 
clotting of human blood. 
Complement deficiencies may be in part responsible for coagulation disorders 
which have not yet been adequately explained by abnormalities of the classically 
described factors. In addition, experiments reported in  the accompanying com- 
munication indicate that activation of complement may initiate blood coagula- 
tion, thus suggesting an important role for complement in intravascular coagu- 
lation syndromes. 
SIfM-MARY 
Evidence for the involvement of the sixth component of complement (C6) in 
normal blood coagulation is provided by the description of a  coagulation ab- 
normality in rabbits  with a  genetic C6  deficiency and bv its correction with 
highly purified preparations of C6. Whole blood clotting time in glass or plastic 
was prolonged and prothrombin consumption was decreased in blood from the ZIMMERMAN, ARROYAVE, Mt~LLER-EBERHARD  1599 
deficient animals. Other parameters of blood coagulation were normal, including 
prothrombin  time,  partial  thromboplastin  time,  specific  clotting  factor  ac- 
tivities, platelet factor III function, platelet count, and bleeding time. Clotting 
time and prothrombin consumption became normal when physiologic amounts 
of highly purified C6 were added to the deficient blood. Partial consumption of 
C6 hemolytic activity,  with  a  time course similar  to the consumption of pro- 
thrombin, was demonstrated during the clotting of normal human blood. 
This manuscript  was reviewed in various stages of preparation  by Doctors Cecil Hougie 
and Oscar Ratnoff whose advice has been most valuable. Dr. Hougie provided the plasmas 
congenitally deficient in coagulation factors, with the exception of factor XI-deficlent  plasma, 
which was provided by Dr. Charles Cochrane. 
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